WO2007088960A1

WO2007088960A1 - Anti-fatigue composition

Info

Publication number: WO2007088960A1
Application number: PCT/JP2007/051767
Authority: WO
Inventors: Shinobu Ugajin
Original assignee: Mizkan Group Corporation
Priority date: 2006-02-03
Filing date: 2007-02-02
Publication date: 2007-08-09
Also published as: JP2007204445A; TW200800152A

Abstract

The object is to provide a safe composition which has an anti-fatigue effect and can alleviate chronic fatigue syndrome, and can prevent the death from overwork. Disclosed is an anti-fatigue composition effective for chronic fatigue. The composition comprises at least one component selected from acetic acid, an acetate ion and an acetate salt as an active ingredient.

Description

Specification

Anti-fatigue composition

Technical field

[0001] The present invention relates to an anti-fatigue composition for recovering or attenuating chronic fatigue.

Background art

[0002] Fatigue includes muscular fatigue (hereinafter sometimes referred to as motor fatigue) caused by temporary intense exercise or physical labor, continuous long working hours, irregular work, and mental fatigue. There is chronic combined fatigue (hereinafter sometimes referred to as chronic fatigue) caused by mechanical stress.

[0003] Chronic fatigue, for example, is often caused by a burden on the work environment or mental stress, such as shift work, night work, long overtime, and holiday work, resulting in temporary physical and mental health. As a result, there is a social problem as well.

[0004] Vitamin C (for example, see Non-Patent Document 1) has been reported to be effective as a symptomatic treatment for chronic fatigue, but its effect is not so strong, and it has an excellent anti-fatigue composition against chronic fatigue. It was hoped that things would be developed.

[0005] However, the molecular and neurological mechanisms related to chronic fatigue are still unknown, and one of the causes is that there are animal models of motor fatigue. The development was delayed.

[0006] On the other hand, in recent years, as a result of the development of model animals for chronic fatigue (for example, see Non-Patent Document 2), for example, popterin, a natural product widely distributed in the skin of insects and amphibians, royal jelly, etc. An anti-fatigue composition for chronic fatigue containing 6R-L-erythro 5, 6, 7, 8-tetrahydropiopterin, a related substance, has been proposed (see, for example, Patent Document 1).

[0007] On the other hand, for acetic acid or vinegar, for example, glycogen decreased by exercise in the liver and muscle by ingesting acetic acid together with glucose during exercise fatigue. Although it has been reported that re-supplementation is promoted and, as a result, motor fatigue is recovered, knowledge about the effect on chronic fatigue has not been disclosed (for example, see Non-Patent Document 3 and Non-Patent Document 4). .

Patent Document 2 discloses an anti-fatigue composition containing Coenzyme Q, carcin and an organic acid.

Ten

It is described that the product is effective for chronic fatigue, acetic acid is exemplified as the organic acid, and specific data using acetic acid is not shown. In addition, the anti-fatigue composition described in Patent Document 2 is effective due to the synergistic effect of the three components of coenzyme Q, carnitine and organic acid.

Ten

It is based on the premise that sufficient effects on chronic fatigue cannot be obtained by using an organic acid alone (paragraphs 0005 to 0006). Furthermore, in Patent Document 3 and Patent Document 4 cited in Patent Document 2 as prior documents related to organic acid-containing compositions, organic acids are polycarboxylic acids (for example, citrate, malic acid, liquor, etc.). It is limited to (acid).

[0009] Thus, findings suggesting that acetic acid or other monocarboxylic acids have an effect on chronic fatigue have been reported so far.

Patent Document 1: Japanese Unexamined Patent Publication No. 2005-15417

Patent Document 2: Japanese Patent Laid-Open No. 2005-97161

Patent Document 3: Japanese Patent Laid-Open No. 10-175856

Patent Document 4: Japanese Patent Laid-Open No. 9-59161

Non-patent document 1: “In Vivo”, 10 卷, No. 6, p. 585-596, 1996 Non-patent document 2: “Neuroscience Let's”, 352 卷, p

159-162, 2003

Non-Patent Document 3: "Journal 'Ob' Nutrition", 131 卷, 7, p. 1973—1977, 2001

Non-Patent Document 4: "International 'Journal' Ob 'Sports Med.'", 23 J, p. 218-222, 2002

Disclosure of the invention

Problems to be solved by the invention

[0010] An object of the present invention is to provide an anti-fatigue composition used to recover or attenuate chronic fatigue. It is to provide.

Means for solving the problem

[0011] The inventors of the present invention have focused on the fact that effective chronic fatigue model animals have been effective as one of the causes of the inability to find effective food ingredients and natural products that recover and attenuate chronic fatigue. Acetic acid and acetic acid using the water immersion breeding / load forced swimming test method (for example, see Patent Document 1 and Non-Patent Document 1), which is a model that reflects the process leading to overwork death due to fatigue and poverty. The inventors have found that at least one selected from ions and acetate has an excellent anti-fatigue effect, and have completed the present invention.

That is, the present invention is as follows.

[0013] (1) An anti-fatigue composition for chronic fatigue comprising at least one selected from acetic acid, acetate ions and acetate as an active ingredient.

[0014] (2) The anti-fatigue composition according to the above (1), prepared so that at least one selected from 0.1 to 2 g (acetic acid equivalent amount) of acetic acid, acetate ion and acetate per day can be ingested object.

[0015] (3) The anti-fatigue composition according to (1) or (2), which does not contain Coenzyme Q.

Ten

[0016] (4) The anti-fatigue composition according to any one of (1) to (3), which does not contain carcin.

[0017] (5) The anti-fatigue composition according to any one of (1) to (4), for treating chronic fatigue syndrome.

[0018] (6) The anti-fatigue composition according to any one of the above (1) to (5) for preventing death from overwork.

The invention's effect

[0019] According to the present invention, so-called chronic fatigue caused by daily chronic stress or work load by ingesting a pharmaceutical or food containing at least one selected from acetic acid, acetate ion and acetate. The best mode for carrying out the invention can be expected to have excellent recovery and attenuation effects

[0020] Hereinafter, the present invention will be described in detail.

[0021] The acetic acid used in the present invention may be one produced by a synthesis method with no particular limitation on the production method or one produced by a fermentation method.

[0022] However, when used as food, it is safer and is manufactured by fermentation. It is preferable to use the acetic acid thus obtained, that is, vinegar (brewed vinegar). Among them, brown rice vinegar, which is hard to feel sourness, apple vinegar having a refreshing fragrance, and the like are more preferable.

[0023] Various acetates such as sodium acetate can be used in that acetic acid can be ingested while reducing acidity.

[0024] The composition of the present invention is dissociated! /, Acetic acid molecules (CH COOH), dissociated acetate ions.

Three

(CH COO_) and undissociated acetate (hereinafter sometimes referred to as “acetic acid”)

Three

At least one selected from the group consisting of active ingredients.

[0025] This is because loca ingested with a low acetic acid solution of ¾H, a neutralized acetate salt (for example, sodium acetate), or a dissociated acetate ion. The pH of the intestinal tract after absorption of the stomach and the small intestine is not significantly affected by the composition of the composition, and is kept almost constant at each site. This is because the presence of acetic acid does not affect the absorption of acetic acid in the body.

[0026] The measurement of acetic acid can be performed using, for example, a carboxylic acid analyzer (EYELA carboxylic acid analyzer S-3000) manufactured by Tokyo Rika Kikai Co., Ltd. The analyzer is a device that separates various organic acids with a column and detects the organic acid by using the principle of specifically reacting with a carboxyl group, and is a vinegar contained in a solution related to dissociation and non-dissociation. Acids can be quantified.

[0027] The composition of the present invention can be used as pharmaceuticals and foods, and pharmaceuticals mean those stipulated in the Pharmaceutical Affairs Law. Tablets, capsules, powders, granules, fine granules, drinks, etc. It can be provided in the form.

[0028] In addition, food means food that is taken orally, and includes all foods that can be administered orally, such as functional foods, health supplements, functional nutritional foods, special-purpose foods, and foods for specified health use. In addition, conventional foods using vinegar such as vinegar, sushi, marinade and vinegar beverages are also included.

[0029] When the composition of the present invention is used as a food, recovery from chronic fatigue 'attenuation, treatment of chronic fatigue syndrome, recovery of chronic complex fatigue' attenuation, prevention of overwork death, etc. It is desirable to use it with the label.

[0030] For the preparation of the composition, acetic acid, acetate ion and acetate are selected according to the type of the composition. It can be obtained by mixing at least one of the above and an appropriate amount of other conventional ingredients (food ingredients, pharmaceutical ingredients).

[0031] For example, in the case of solid preparations, excipients, binders, disintegrants, fillers, fillers, moisturizers, surfactants, lubricants, etc. can be used. Adjuvants, suspending agents, buffering agents, etc. can be used. In addition, preservatives, solubilizers, emulsifiers, dispersants, thickeners, plasticizers, adsorbents, fragrances, colorants, flavoring agents, sweeteners, preservatives, antioxidants, etc. are used as necessary. Is possible.

[0032] Examples of the excipient include lactose, sucrose, oligosaccharide, maltitol, sorbitol, xylitol, and mannitol. Examples of the binder include crystalline cellulose, dextrin, hydroxypropyl cellulose, hydroxy Examples thereof include propylmethyl cellulose, polyvinyl pyridine, and gum arabic.

[0033] Examples of the disintegrant include starch, carboxycellulose, and carboxymethylcellulose strength. As the lubricant, magnesium stearate, calcium stearate, colloidal silica or the like is used.

[0034] As the solvent, for example, physiological saline, alcohol, propylene glycol, macrogol, sesame oil, corn oil and the like can be used, and as the solubilizer, ethanol, polyethylene glycol and the like can be mentioned.

[0035] Examples of the suspending agent include surfactants such as sodium lauryl sulfate, lecithin, and dallyseline monostearate, and hydrophilic polymers such as polybutyl alcohol, hydroxymethylcellulose, and hydroxymethylpropylcellulose. It can be illustrated.

[0036] Examples of the preservative include para-benzoic acid ester, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like.

[0037] As the colorant, tar dyes, titanium oxide, etc. can be used. Examples of the flavoring agent include citrate, adipic acid, ascorbic acid, menthol and the like. Examples of the antioxidant include sulfite. Salt, ascorbic acid and the like.

[0038] Furthermore, additives such as other physiologically active substances, minerals, vitamins, hormones, nutritional ingredients, and fragrances can be mixed as necessary.

[0039] The method for adding acetic acid may be a general method with no particular limitation. When using in the form of a low pH solution such as synthetic acetic acid or brewed vinegar in which the acid is in the form of a salt, it is necessary to pay attention to the “plum” due to low pH due to the ease of eating and drinking. Specifically, when ingesting a low pH solution, problems such as soaking occur, so when acetic acids are contained at high concentrations, use of acetate, etc. and Z or encapsulation, etc. You can take this form.

[0040] On the other hand, the dose or intake of acetic acid according to the present invention is determined depending on the sex, age, weight, and symptoms, administration time, dosage form, administration method, combination of drugs, etc. of the recipient. For example, it is preferable to administer 0.1 g to 2 g per person per day, more preferably 1 to 2 g.

[0041] In this case, the number of intakes per day need not be limited to one, and can be divided into several times during the day.

[0042] By the way, in animal experiments, an effect was observed by administering 0.01 to 0.02 g of acetic acid to rats. When this result is converted to humans, it is generally 10 to: L00 times. Therefore, ingesting 0.lg to 2g per person per day is considered effective.

[0043] The concentration of acetic acid added to the composition is preferably about 0.1 to 2 g per 1 kg of the composition as the amount of acetic acid. If the concentration is lower than this, it is necessary to take a very large amount of a composition such as a drink or a tablet. Here, the intake amount per day is calculated and set based on about 1 kg or 1 liter.

[0044] The necessary amount of effective acetic acid molecules can also be obtained by ingesting about 50 to 200 ml of a drink containing vinegar such as apple vinegar per day.

[0045] In addition, in the case of a high concentration and when using non-neutralized acetic acid, an intake method that takes into account damage to the digestive tract such as the stomach and intestine is desirable.

Brief Description of Drawings

FIG. 1 is a diagram showing a relative value of an average time required for submergence in a weight load forced swimming test in Example 1.

FIG. 2 is a graph showing the results of measuring the liver glycogen concentration in Example 1.

FIG. 3 is a diagram showing the results of measuring the concentration of soleus muscle glycogen in Example 1. FIG. 4 shows the results of measuring the glycogen concentration of gastrocnemius muscle in Example 1.

FIG. 5 is a diagram showing a relative value of an average time required for submergence in the weight load forced swimming test in Example 2.

[0047] This specification includes the contents described in the specification and Z or drawings of Japanese Patent Application No. 2006-026920, which is the basis of the priority of the present application.

Example

[0048] The ability of the present invention to be described below with reference to examples. The present invention is not limited to these examples.

[0049] (Example 1)

Seven-week-old male SD rats were raised for 5 days in cages adjusted to a water depth of 1.5 cm with a water temperature of 23 ° C ± 1 ° C. From the first day, physiological saline (3 mlZday) and ascorbic acid were intraperitoneally administered (30 mgZkgZday) or orally (300 mgZkgZday), and acetic acid was orally administered (30 mgZkgZday). The physiological saline intraperitoneal administration group was the control group (n = 12), the ascorbic acid intraperitoneal administration group was the positive control group (n = 8), and the test group was the ascorbic acid oral administration group (n = 8), Acetic acid was orally administered (n = 12).

[0050] Next, in order to investigate the effect of attenuating chronic fatigue, 24 hours after the administration on the fifth day, the physiological saline intraperitoneal administration group (control group) (n = 12) 8 of the ascorbic acid intraperitoneal administration group (positive control group) (n = 8), ascorbic acid oral administration group (n = 8), and acetic acid oral administration group (n = 12) Swim the rat with 10% weight loaded, measure the time until the nose submerged for 10 seconds or more, and set the average time in the saline intraperitoneal administration group (control group) to 100 The results showing the average time of each administration group as% are shown in FIG.

[0051] At the same time, in order to examine whether this test system shows a known glycogen supplementation promoting effect by acetic acid, after the administration power of 24th day on the fifth day, the saline intraperitoneal administration group (control group) ( The remaining 4 of _n = 12) and the remaining 4 of the acetic acid oral administration group (n = 12) were dissected under ether anesthesia, and the liver and muscles (soleus and gastrocnemius) were immediately removed. Stored at ° C. And the glycogen content in the tissue of each group was measured. The obtained results are shown in FIGS. [0052] From the results shown in Fig. 1, it was found that ascorbic acid and acetic acid enable longer swimming in the weight-load forced swimming test than in the physiological saline intraperitoneal administration group (control group). did. Furthermore, it was confirmed that ascorbic acid administration was less effective when administered orally than in intraperitoneal administration, whereas acetic acid enabled long-term swimming when administered orally.

[0053] Furthermore, from the results of Figs. 2 to 4, it was confirmed that there was no difference in the amount of glycogen in each tissue when water was ingested and when acetic acid was ingested. 3 and non-patent document 4), the glycogen replenishment effect of acetic acid observed in (3) and non-patent document 4) is different from the fact that carbohydrates are not ingested simultaneously with acetic acid. In the present invention, glycogen resupplementation may not be accelerated. confirmed.

[0054] That is, it was considered that the fatigue attenuation effects such as acetic acid, acetate ions, and acetate observed in the weight-load forced swimming test did not depend on the amount of glycogen stored in each organ. Based on the above, it is considered that acetic acid is effective in reducing fatigue without taking carbohydrates at the same time, and is suitable for reducing chronic fatigue by ingestion, regardless of the form of intake. .

[Example 2]

In order to examine the effect of reducing chronic fatigue at different acetic acid concentrations, 7-week-old male SD rats were raised for 5 days in cages adjusted to a water depth of 1.5 cm with a water temperature of 23 ° C ± 1 ° C. From the first day, physiological saline (3 mlZday) and ascorbic acid were intraperitoneally administered (30 mgZkgZday) or orally (300 mgZkgZday), and acetic acid was further orally administered (30 mgZkgZday and 60 mgZkgZday).

[0056] The physiological saline intraperitoneal administration group was the control group (n = 8), the ascorbic acid intraperitoneal administration group was the positive control group (n = 8), and the test group was the low-acetate oral administration group (30 mg / kg / day) (n = 8) and acetic acid high dose oral administration group (60 mgZkgZday) (n = 8).

[0057] Next, in order to investigate the effect of reducing chronic fatigue, after 24 hours from the administration on the fifth day, the rats were allowed to swim with a weight of 8% of the body weight loaded, Measure the time it takes for the nose to submerge for 10 seconds or longer. FIG. 5 shows the results showing the average time of each administration group, with the time as 100%.

[0058] From the results shown in Fig. 5, when acetic acid was administered, it was possible to swim for a longer period of time compared to the control group, even in the case of deviation between oral administration of acetic acid at a low dose and oral administration of acetic acid at a high dose. It was confirmed that the effect was equal to or better than ascorbic acid.

[0059] (Example 3)

A drink was prepared with the following composition. In other words, 155 ml of apple vinegar, 100 ml of apple juice, 10 g of honey, 0.1 g of sucralose, 0.1 g of citrate and vitamin CO. Olg are mixed and dissolved as 1 litter to prepare a drink containing about 7 g of acetic acid. did. The drink is moderately sour and has a refreshing and drinkable quality. Due to the effect of acetic acid, it is about 100 to 200 ml per day (0.7 to 1.4 g of acetic acid). It was considered possible and suitable for expectation of fatigue reduction for chronic fatigue by oral intake.

[Example 4]

Tablets were produced with the following composition. That is, tablets containing 2.5 g of sodium acetate per 100 g of tablets (50 mg per tablet) were produced. By ingesting 12 g (6 tablets, 0.3 g of acetic acid) of the tablet per day, fatigue reduction against chronic fatigue can be expected.

[0061] All publications, patents and patent applications cited in this specification are incorporated herein by reference in their entirety.

Industrial applicability

[0062] The present invention is used as a pharmaceutical or food for recovering or attenuating chronic fatigue.

Claims

The scope of the claims

[1] An anti-fatigue composition for chronic fatigue comprising at least one selected from acetic acid, acetate ions and acetate as an active ingredient.

[2] The anti-fatigue composition according to claim 1, wherein the anti-fatigue composition is prepared so that at least one selected from 0.1 to 2 g (acetic acid equivalent amount) of acetic acid, acetate ion and acetate can be taken per day.

[3] The anti-fatigue composition according to claim 1 or 2, which does not contain Coenzyme Q.

Ten

[4] The anti-fatigue composition according to any one of claims 1 to 3, which does not contain carcin.

[5] The anti-fatigue composition according to any one of claims 1 to 4, for treating chronic fatigue syndrome.

[6] The anti-fatigue composition according to any one of claims 1 to 5, for preventing death from overwork.